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Hormone therapy revisited
The last shots in the hormone replacement therapy (HRT)
battle have not been fired, but the big guns of large
randomised clinical trials (RCTs) are rapidly neutralising myths
that have persisted for decades. Two articles in this journal
keep up the pressure in favour of evidence-based medicine.
Rosenberg and Hoffman (p. 26) may appear to take a more
abolitionist stance, but they argue mainly against the use of
HRT for disease prevention. Davey (p. 23) argues more
pragmatically on the basis of the importance of symptom
control.
Findings from several large RCTs provide important major
conclusions, including:
• Postmenopausal HRT should not be used to reduce the risk
for coronary heart disease events for women with coronary
heart disease.
• Evidence strongly supports that initiating HRT in women
with previous venous thromboembolism probably increases
the risk of recurrent venous thomboembolism.
• Oestradiol does not reduce the mortality or the recurrence of
stroke in postmenopausal women with cerebrovascular
disease and should not be used for its prevention.
• Breast cancer was significantly increased by HRT, and it was
more advanced in such cases.
• The incidence of colorectal cancer decreases with HRT.
• Hip fractures were reduced by HRT.
• The incidence of dementia was increased in HRT users
relative to placebo (thus going against suggestions that
quality of life and brain function are improved by the use of
HRT).
Davey notes that the relief of menopausal symptoms is the
prime overwhelming need for many, if not most,
postmenopausal women. The relief of postmenopausal
symptoms was not included in the Women’s Health Initiative
trial. Relief of symptoms must be given due weight in any
assessment of the benefits and risks of HRT. He concludes that
the balance of benefits and risks in individual women varies
greatly. HRT must be individual, and each woman has to come
to a personal decision with the help and advice of her clinician.
Chloroquine blindness
With the increase in the incidence of malaria in our region the
use of antimalarials has been increasing. Many clinicians will
be surprised to hear that many patients in South Africa
develop profound visual loss every year as a result of
chloroquine toxicity. Kelvin Rivett addresses this important
matter (p. 41) and proposes a solution to the problem. 
Chloroquine is used as prophylaxis against malaria and is
also prescribed for the treatment of amoebiasis, rheumatoid
arthritis, etc. It is excreted from the body very slowly and
becomes concentrated in the melanin-containing cells of the
retinal pigment epithelium and choroid. Most cases of toxicity
occur when a higher than recommended dose is used. Retinal
toxicity and degeneration occur and are a severe sight-
threatening complication of chloroquine use. The chloroquine
daily dose is thought to be more important than the cumulative
dose and should be tailored according to gender and height.
Chloroquine-related blindness has been almost completely
eradicated in countries where hydroxychloroquine is freely
available. Rivett strongly advocates such a switch in South
Africa.
Haemophilus influenzae vaccines
We are reminded that Haemophilus influenzae type b (HiB)
remains the principal cause of invasive bacterial diseases in
under-5-year-olds in developing countries. Vaccines have
proved to be effective in reducing transmission rates and
protecting the children at risk from invasive HiB disease, in the
developing countries in which the HiB vaccines are now used.
Matjila and colleagues (p. 43) compared the safety and
immunogenicity of two vaccines, VaxemHib and HibTITER.
They followed the World Health Organisation’s accelerated
schedule which allows 4-week intervals between the doses.
They concluded that both vaccines showed comparable safety
and immunogenicity when administered to South African
babies at 6, 10 and 14 weeks of age.
Resistance to malaria
Severe malaria in the Comoros Union and in Madagascar is
invariably caused by Plasmodium falciparum, as it is in the rest
of sub-Saharan Africa. Barnes and Folb, in an editorial, address
the complexities of measuring the resistance to malaria (p. 46)
in response to an article from Madagascar (p. 47). The latter
submit, on the basis of their findings, that current policy for the
treatment of severe malaria with a 7-day course of quinine, and
prophylaxis with either mefloquine or cycloguanil-based
regimens, are justified by their in vitro laboratory findings.
As malaria morbidity and mortality are rising, principally as
the result of increasing antimalarial resistance, Barnes and Folb
evaluate the interesting and important conclusions. They
address the use of the drugs and the various factors that
encourage the spread of resistance, including the proportion of
transmissible malaria infections exposed to sub-therapeutic
concentrations of drug, the drug concentration profile, the
pattern of drug use, and the level of immunity in the
community. Resistance frequently develops first to the
antimalarials most widely used in the treatment of
uncomplicated malaria.
In vitro testing does not allow for drug behaviour in the body
— the absorption, metabolism, distribution and elimination
characteristics that significantly affect the antimalarial action of
drugs. Nor can it take into account the complex immune
response that takes place in conjunction with the drug action.
Laboratory methods would have to be standardised, and
more general agreement is needed on how in vitro laboratory
findings might be used in deciding on policy change and in
comparing the situation between countries and regions.
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